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Summarv Urinary gonadotropin peptide (UGP) lesels wvere determined in urine samples from 450 Egyptian
subjects to determine its relative level of expression in benign and malignant urological disease. and normal
individuals. The mean UGP lesvel in patients with bladder cancer swas 44-fold hiaher than in patients with
benign disease. and 81-fold higher than in normal individuals. At specificities of 950o and 100°o. overall
sensitivities of 730o and 60°o. respectisvelv. were obsersved for the detection of malignant disease. Mean UGP
levels in patients with bladder cancer swere significantlv correlated with the stage and grade of malignant disease
but did not svarv significantlvs when stratified according to histological type of disease. nodal insolsement or
bilharzial association. UGP could be a potentially useful marker for the differentiation of benign from
malignant urological disease.
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In Eg-pt. bladder cancer is the most common type of male
malignancy. ranking only after breast cancer in females in
rate of incidence. The disease is characten'sed bs a
predominance of locallv adsanced lesions and a high
incidence of squamous cell carcinoma (Khaled. 1993). There
is a close relationship betus-een the prevalence of urinanr tract
schistosomiasis and the incidence of bladder cancer. A
positive history of schistosomiasis or repeated treatment of
schistosomiasis with anti-bilharzial drugs are correlated With
bladder cancer in 9000 of patients (Mustacchi and Shimnkin.
1958: El-Sebai. 1961: Al-Shukri et al.. 1987). Different
tumour markers have been evaluated for detecting Egyptian
bladder cancer. With varying results in terms of sensitivitv
and specificity (El-Ahmadx et al.. 1991a. 1992a. b). To date.
tissue polypeptide antigen (TPA) has been the most reliable
marker and the combined use of carcinoembryonic antigen
(CEA) and ferritin with TPA has increased the diagnostic
value of TPA in detecting bladder cancer (El-Ahmady. 1988.
1990: Halim et al.. 1992. 1993). Urinary levels of human
chorionic gonadotropin beta subunit (beta-hCG) have also
been evaluated in Egyptian bladder cancer patients and
patients with benign urinary tract disorders. This marker was
elevated in 60.3% of cancer patients. however 29.7% of
patients u ith benign disease were also elevated above the
upper limit of the normal control group (Halim et al.. 1994).
Urinar- gonadotropin peptide (UGP). also known as
unnary gonadotropin fragment (UGF) and beta-core
fragment. is a 10.5 kDa glycoprotein with a primar-
sequence identical to residues 6-40 and 55-92 of the beta-
subunit of human chorionic gonadotropin (hCG) (Birken et
al.. 1988). The carbohvdrate moieties of UGP differ
significantly from hCG. lacking all 0-linked species and
retaining only the core mannose. N-acetylglucosamine and
fucose residues (Bl-the et al.. 1989: Endo et al.. 1989).
UGP is measured in urine and is deri'ved from the
degradation of ectopic hCG at multiple locations. including
the tissue of origin. the circulation and the kidneys (Cole.
1994). UGP is highls stable in urine and studies with
pregnancy urines hase indicated that samples can be stored
at 4^C or 25'C for 21 days. or -20C for 6 months.
Preservatisves are not required to maintain clinical sample
stability (de Medeiros et al.. 1991). UGP is not readily
measured in serum owing to its rapid clearance rate from the
circulation.
UGP is a major component of pregnancy urine. in which
it was first described (Franchimont et al.. 1972: Kato and
Braunstein. 1988). It has subsequently been shown to occur
in the urine of patients with a variety of non-trophoblastic
tumours (Papapetrou et al.. 1980). including colorectal cancer
(McGill et al.. 1990). pancreatic and biliary cancer. gastric
cancer (Alfthan et al.. 1992) and lung cancer (Yoshimura et
al.. 1994). Immunohistochemical studies have demonstrated it
to be expressed by a w-ide v-ariety of tumour tissues (Kardana
et al.. 1988). To date. most studies have focused on its
expression in gynaecological cancers. UGP is expressed in a
stage-dependent manner in the urine of patients with cervical
cancer (Norman et al.. 1990). endometrial cancer (Nam et al..
l990a). N-ulvar cancer (Nam et al.. 1990b) and ovarian cancer
(Cole and Nam. 1989).
The objective of this study wvas to evaluate the expression
of UGP in preoperative patients with invasisve bladder cancer
and benign urological disease and in normal individuals in
order to determine its potential use as a marker in the
management of this malignancy.
Patients and methods
Patients
The present study included 450 indiv-iduals classified into
three groups. The first group included 237 patients with
urinary bladder cancer who w-ere admitted to the Egyptian
National Cancer Institute. This group consisted of 171 males
and 66 females ranging in age from 24 to 78 years. with a
mean age of 52 y-ears. Lymph node involvement w-as present
in 32 patients and absent in 205 patients. Tumour staging
was carried out according to UICC cnrtenra and grading A-as
according to an established method (Beahrs et al.. 1988).
Histopathological examination of the tumour tissues indi-
cated 134 squamous cell carcinomas. 83 transitional cell
carcinomas. ten adenocarcinomas. tw-o verrucous carcinomas.
tw-o leiomyosarcomas and six undifferentiated carcinomas. As
a function of stage. 14 patients A-ere stage T I and T II. 179
patients w-ere stage T III and 44 patients w-ere stage T IV.
When stratified by grade. 41 patients were grade 1. 118
patients A-ere grade 2 and 78 patients were grade 3. Bilharzial
ova were identified in 143 tumours and absent in 94 tumours.
The second group consisted of 97 patients with benign
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urinary tract disease recruited from the urology outpatient
clinic, Kasr El-Aini Hospital, and included 90 males and
seven females ranging in age from 19 to 63 years, with a
mean of 28 years. The benign disease categories included 83
patients with urinary tract bilharziasis and 14 with other
benign disorders including benign prostatic hyperplasia, renal
stones, varicocele and bladder ulcers. The third group
included 116 normal healthy controls who were free of
disease as evidenced by clinical and laboratory investigations.
This group consisted of 107 males and nine females ranging
in age from 20 to 52 years, with a mean age of 26 years, who
were recruited from students and workers at Al-Azhar
University, Cairo, Egypt. All individuals were requested to
collect 24 h urines. Approximately 10 ml of each urine
sample was centrifuged at 2000-3000 g for 10 min, and the
supernatant was frozen at -80:C until analysed.
Methods
Urinary gonadotropin peptide (UGP) was determined in
freshly thawed urine samples. UGP was measured using an
enzyme-linked inmunoassay (Triton UGP EIA, Ciba
Corning Diagnostics, Alameda, USA). The Triton UGP
EIA is a double-determinant enzyme immunoassay that uses
a monoclonal capture antibody immobilised on a coated tube
and an affinity-purified polyclonal antibody conjugated with
horseradish peroxidase as the detection antibody. The assay
has a minimum detectable concentration of 0.1 fmol ml-'.
Recovery of known quantities of UGP spiked into urne
samples ranged from 86% to 109%, with a mean of 96%.
The intra- and interassay reproducibility ranged from 4.12%
to 4.95% and from 6.07% to 7.85%, respectively, over the
range of the assay. Pathological urine samples exhibited
linear dilution response, with a mean correlation coefficient of
0.999. The assay is highly specific for UGP, exhibiting the
following molar cross-reactivities: human chorionic gonado-
tropin (hCG, 0.11%), hCG beta-subunit (0.043%), hCG
alpha-subunit (0.009%), human luteinising hormone (hLH,
0.001%), hLH beta-subunit (0.005%), human thyroid-
stimulating hormone and beta subunit (hTSH and hFSH
beta-subunit, <0.001%) and human follicle-stimulating
hormone and beta subunit (hFSH and hFSH beta-subunit,
<0.001%). The assay has been optimised to eliminate cross-
reactivity with fragments derived from luteinising hormone
that are present in urine. The following urinary analytes do
not interfere with the assay at levels up to the following
concentrations: urea (5 g dl-'), uric acid (150 mg dl-'),
creatinine (500 mg dl-'), creatine (200 mg dl-1), vitamin C
(500 mg dl-'), urobilin (4 mg dl-'), glucose (30 mg dl-') and
haemoglobin (10 mg dl-'). The acceptable pH range of urine
samples is from 5.5 to 8.5.
UGP values are reported in units of fmol ml-' in the 24 h
urine samples. Statistical analyses were performed using JMP
software (SAS Institute). Population medians were compared
using the Kruskal-Wallis rank-sum test.
Resuls
UGP levels were determined in 450 timed 24 h urine samples
from normal individuals, subjects with benign urological
disease and subjects with invasive bladder cancer. The
normal, benign disease control and cancer patient cohorts
were predominantly male, consisting of 107 (92%), 90 (93%)
and 171 (72%) men respectively. The distribution of UGP
values in these subject categories is described in Table I. The
mean UGP level in the bladder cancer patients was
4.86 fmol ml-', which differed markedly from the mean
value for normal subjects at 0.06 fmol ml-' and
0.11 fmol ml-' for the benign urological disease patients.
The median UGP levels in the benign disease and normal
populations differed significantly from that of the cancer
population (P<0.0001), but did not differ significantly from
each other.
In order to evaluate the clinical performance of the UGP
assay in distinguishing malignant disease from benign disease
and normal individuals in this population, two cut-offs were
used. These cut-offs were 0.7 and 1.4 fmol ml-', which were
the 95th and 100th centiles of the benign disease population.
Using these cut-offs, the epidemiological sensitivity of UGP
for detecting bladder cancer was evaluated as a function of
various clinical parameters.
Table H shows the expression of UGP in 116 normal
subjects and 97 patients with benign urological disease. The
majority of disease control patients (n =83, 86%) had benign
urinary bilharziasis. Mean UGP levels in the normal and
disease control populations were similar and ranged from 0
to 0.13 fmol ml-1. Fewer than 1% of normal individuals and
6% ofpatients with benign disease had UGP levels exceeding
the 0.7 fmol ml-' cut-off. The benign bilharziasis group
showed the greatest number of patients exceeding the
0.7fmolmF1 cut-off at 6.0%. None of the patients exceeded
the 1.4 fmol ml-' cut-off.
Table IH shows the expression of UGP in bladder cancer
patients as a function of various parameters. The mean UGP
value for all patients was 4.86 fmol ml-'. As a function of
Table I Distribution ofUGP values in normal subjects, patients with benign urological disease and patients
with bladder cancer
No. of UGP value (fmolml- )
Category patients Mean Median 75th centile With centile 97.5th centile Range
Normal 116 0.06 0.00 0.02 0.18 0.65 0-0.8
Benign disease 97 0.11 0.00 0.00 0.62 1.25 0-1.37
Bladder cancer 237 4.86 2.31 7.81 14.51 17.06 0-20.2
Table H Expression of UGP in normal and control subjects
No. of UGP (fmolml-') Number (%)
Iexceeding cut of/ Range
Category patients Mean 95th centile 0.7fmolml-F 1.4fmolml (fmolml-t
Normala 116 0.06 0.18 1 (0.9) 0 0-0.8
Benign unnary
tract diseaseb
Bilhariasis 83 0.13 0.70 5 (6.0) 0 0-1.37
OtherC 14 0.0 0.00 0 0 0-0.0
Total benign 97 0.11 0.70 5 (5.2) 0 0-1.37
a,07 male, nine female.bNOmale, seven female.'Benignprostatichyperplasia, renal stones, varicocele,
bladder ulcer.UGP in blgui and -NV
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Table m Expression of UGP in patients with bladder cancer
No. of UGP (fmolml-r) Number (%) exceeding cut off Range
Category patients Mean Median 0.7fmolmr-I 1.4fmolml- (fmolmf-1)
Breakdown by histological type
SCC 134 4.84 2.35 87 (65) 81 (60) 0-20.2
TCC 83 5.40 3.04 59 (71) 52 (63) 0-18.5
Othera 20 2.76 1.11 10 (50) 10 (50) 0-15.1
Breakdown by stage
Stage T I and II 14 3.22 1.94 9 (64) 8 (57) 0-12.0
Stage T III 179 4.64 2.04 127 (71) 102 (57) 0-20.2
Stage T IV 44 6.24 5.71 36 (81) 32 (73) 0-16.5
Breakdown by grade
Grade 1 41 2.93 1.31 27 (66) 18 (44) 0-16.0
Grade 2 118 5.67 3.28 88 (75) 78 (66) 0-20.2
Grade 3 78 4.66 2.28 57 (73) 46 (59) 0-18.5
Breakdown by nodal status
Negative 205 4.86 2.31 149 (73) 123 (60) 0-20.2
Positive 32 4.88 2.26 23 (72) 19 (59) 0-17.0
Breakdown by presence of
bilharzial ova in tumour tissue
Negative 93 4.83 2.14 67 (72) 58 (62) 0-19.0
Positive 143 4.82 2.48 104 (73) 83 (58) 0-20.2
Total cancerb 237 4.86 2.31 172 (73) 142 (60) 0-20.2
aAdenocarinoma, undifferentiated carcinoma, verrucous carcinoma, leiomyosarcoma. b171 male, 66 female.
histological type, patients with squamous cell carcinoma
(SCC) and transitional cell carcinoma (TCC) had the highest
mean UGP levels of 4.84 and 5.40 fmol ml-' respectively.
Patients with other histological types of malignant disease,
including adenocarcinoma, undifferentiated carcinoma, ver-
rucous carcinoma and leiomyosarcoma had a mean UGP
level of 2.76 fmol ml'-. The differences in the mean UGP
levels between these histotypes were not statistically
significant. The percentage of patients exceeding both cut-
offs was similar for the TCC and SCC patients, for example
65% of SCC patients and 71% of TCC patients exceeded the
cut-off of 0.7 fmol ml-'. Patients with other histological
types of disease exceeded both cut-offs in 50% of all cases.
Analysis of bladder cancer patients according to stage of
disease is shown in Table III. A trend of increasing UGP
values with advancing stage was observed from
3.22 fmol ml-' for stage T I and T II patients to
4.64 fmol ml-' for stage T Ill patients to 6.24 fmol ml-' for
stage T IV patients. Median UGP values were significantly
different between the stage T Ill and stage T IV patients
(P=0.05) and between the combined stage Tl and T2 patients
and stage T IV patients (P=0.05) but not between the
combined stage T I and T II patients and the stage T III
patients. Similarly, the percentage of patients exceeding the
cut-off levels increased as a function of stage. At the
0.7 fmol ml-' cut-off, 64% of stage T I and T H patients,
71% of patients with stage T III disease and 81% of stage
T IV patients exceeded the cut-off. The number of patients
exceeding the 1.4 fmol ml-' cut-off followed the same trend
but was correspondingly lower, ranging from 57% ofstate T I
and T II patients to 73% of stage T IV patients.
When bladder cancer patients were stratified according to
grade ofdisease (Table HI), mean UGP levels were lowest for
grade 1 patients, and higher but similar for grade 2 and 3
patients. Grade 1 patients had a mean UGP level of
2.93 fmol ml-' and grade 2 and 3 patients had mean UGP
levels of 5.67 and 4.66 fmol ml-' respectively. Median UGP
levels were significantly different between grade 1 and grade 2
patients (P=0.006) but not between grade 2 and 3 patients.
Overexpression of UGP values was similar for all grades at a
cut-off of 0.7 fmol ml-', with 66% of grade 1 patients and
75% and 73%, respectively, of grade 2 and 3 patients
exceeding the cut-off. At the higher cut off of 1.4 fmol ml-',
the percentage of patients with grade 1 disease exceeding the
cut-off was 44%, which was significantly lower than that for
the grade 2 (66%) and grade 3 (59%) patients.
Stratification ofbladder cancer patients according to nodal
status and the presence of bilharzial ova in the tumour tissue
is shown in Table III. For both categories, mean UGP levels
in negative and positive cases were virtually identical to each
other and to the mean value for all cancer patients, ranging
from 4.82 to 4.88 fmol ml-'. Similarly, overexpression rates
at both cut-offs were virtually identical to each other and to
the value for all cancer patients, ranging from 72-73% at the
0.7 fmol ml-' cut-off, and 58-62% at the 1.4 fmol ml-' cut-
off. Finally, stratification of bladder cancer patients
according to gender showed no difference in mean UGP
levels (data not shown).
DiKmsion
UGP is a pan-marker and has been demonstrated to be
expressed in the urine of patients with a variety of solid
tumours. Most studies have focused on evaluating the utility
of UGP in the management of malignant gynaecological
disease, although significant elevations have been observed in
other types of malignancies. This study demonstrated that
UGP is also overexpressed in a majority of Egyptian patients
with advanced stage bladder cancer. The source of UGP in
the urine of patients with malignant disease is the metabolic
breakdown of hCG species, predominantly hCG beta
subunit, originating in the tumour tissue. This is corrobo-
rated by previous reports that have demonstrated the
presence of hCG beta subunit in the tissues and circulation
ofapproximately 50% ofpatients with bladder cancer (Oliver
et al., 1988; Marcillac et al., 1992). Other studies have shown
that UGP was present in the urine of patients with hCG-
producing bladder tumours (Iles et al., 1990). Because UGP
is the predominant hCG-derived species in urine, it is the
most sensitive marker of hCG immunoreactivity for
indicating the presence of malignancy. An additional factor
contributing to the high level of UGP overexpression in this
population of bladder cancer patients could be the relatively
high proportion with advanced disease.
In this study population, UGP was demonstrated to be a
sensitive and specific marker for malignancy. UGP was only
marginally elevated in samples from normal individuals and
in patients with benign urological disease. Mean UGP levels
in patients with bladder cancer were 81-fold and 44-fold
higher than those in normal individuals and patients with





levels, overall sensitivities of 73% and 60%, respectively,
were observed. A statistically significant increase in median
UGP level as a function of stage and grade was observed, but
no correlation with histological type, nodal involvement or
bilharzial association was demonstrable.
The sensitivity of UGP for detecting malignancy in this
population of Egyptian bladder cancer patients was
comparable with or better than that of other tumour
markers. At specificities of 95% and 100%, sensitivities of
73% and 60% respectively were observed. By comparison, at
95% specificity, urinary squamous cell antigen (SCC antigen),
ferritin, CEA and TPA were elevated in 24%, 72%, 62% and
81% respectively, of patients with bladder cancer (El-
Abmady et al., 1992a, b; Halim et al., 1992). However, at
100% specificity, the sensitivities of ferritin, CEA and TPA
dropped markedly to 34%, 23% and 34% respectively.
The UGP cut-offs used in this study are lower than those
used in other studies reported in the literature. This could be
due to several factors. First, the levels of UGP in cancer
patients could be expected to vary according to tumour type.
Second, the populations in this study were predominantly
male. Earlier studies have shown that the normal range of
UGP is measurably higher in post-menopausal women
compared with males and premenopausal women (Lee et
al., 1991). Finally, this study used 24 urines for UGP
determination and the majority of studies reported in the
literature with this marker use spot urines, usually corrected
for creatinine. Because spot or early-morning spot urines are
more readily obtainable than timed 24 h urines, future studies
will evaluate the correlation between 24 h urines and spot
urines corrected for creatinine.
Owing to its high sensitivity for detecting individuals with
malignant disease at a cut-off at which no false-positives were
observed in patients with benign urological disease, the
clinical value of UGP could be for the differential diagnosis
of these patients, particularly in high-risk populations. The
application of this marker for this use needs to be evaluated
in further studies.
The use of UGP is facilitated by the fact that it is a highly
stable marker that is measurable in urine, which is a readily
obtained and non-invasive sample. Future studies will focus
on evaluating UGP expression in early stage disease, as well
as for monitoring and detecting recurrent disease.
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